دورية أكاديمية
أعرض في EDS

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma.

التفاصيل البيبلوغرافية
العنوان: Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma.
المؤلفون: Davis LN; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Sherbenou DW; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.; Department of Blood Disorders and Cell Therapies, University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA.
المصدر: Cancers [Cancers (Basel)] 2021 Apr 02; Vol. 13 (7). Date of Electronic Publication: 2021 Apr 02.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Multiple myeloma is a malignant plasma cell neoplasm that remains incurable and is ultimately fatal when patients acquire multi-drug resistance. Thus, advancing our understanding of the mechanisms behind drug resistance in multi-relapsed patients is critical for developing better strategies to extend their lifespan. Here, we review the understanding of resistance to the three key drug classes approved for multiple myeloma treatment: immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. We consider how the complex, heterogenous biology of multiple myeloma may influence the acquisition of drug resistance and reflect on the gaps in knowledge where additional research is needed to improve our treatment approaches. Fortunately, many agents are currently being evaluated preclinically and in clinical trials that have the potential to overcome or delay drug resistance, including next-generation immunomodulatory drugs and proteasome inhibitors, novel small molecule drugs, chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies. For each class, we discuss the potential of these strategies to overcome resistance through modifying agents within each class or new classes without cross-resistance to currently available drugs.
References: Nat Chem Biol. 2019 Jul;15(7):681-689. (PMID: 31133756)
Mol Cancer Ther. 2016 May;15(5):1132-44. (PMID: 26939706)
Blood. 2019 Apr 4;133(14):1572-1584. (PMID: 30737236)
Pharmacol Res. 2016 Mar;105:210-5. (PMID: 26827824)
Mol Immunol. 2011 May;48(9-10):1272-8. (PMID: 21477865)
Oncotarget. 2015 Jun 20;6(17):14814-31. (PMID: 26109433)
J Immunol. 2011 Feb 1;186(3):1840-8. (PMID: 21187443)
Elife. 2015 Sep 01;4:e08153. (PMID: 26327694)
Cancer Treat Rev. 2018 Nov;70:199-208. (PMID: 30245231)
Leuk Lymphoma. 2015 Jan;56(1):26-33. (PMID: 24678978)
Blood. 2016 Sep 1;128(9):1214-25. (PMID: 27443291)
Leukemia. 2015 Mar;29(3):705-14. (PMID: 25102946)
Blood. 2017 Nov 30;130(22):2392-2400. (PMID: 28847998)
J Cell Mol Med. 2014 Jun;18(6):947-61. (PMID: 24712303)
Cancer Cell. 2005 Nov;8(5):407-19. (PMID: 16286248)
Blood. 2016 Sep 1;128(9):1226-33. (PMID: 27458004)
Transl Oncol. 2017 Aug;10(4):632-640. (PMID: 28668761)
Ann Hematol. 2014 Aug;93(8):1371-80. (PMID: 24687382)
Nat Commun. 2017 Nov 20;8(1):1613. (PMID: 29151572)
Ther Adv Hematol. 2018 Jul;9(7):175-190. (PMID: 30013765)
Blood Adv. 2020 Sep 22;4(18):4538-4549. (PMID: 32956453)
Blood. 2021 Jan 14;137(2):232-237. (PMID: 33443552)
Oncotarget. 2017 Jun 8;8(39):66641-66655. (PMID: 29029544)
MAbs. 2015;7(2):311-21. (PMID: 25760767)
Int J Oncol. 2013 Dec;43(6):1809-16. (PMID: 24126540)
Cancer Cell. 2013 Sep 9;24(3):289-304. (PMID: 24029229)
Leukemia. 2019 Aug;33(8):2006-2021. (PMID: 30760870)
Blood. 2006 Nov 15;108(10):3441-9. (PMID: 16728695)
N Engl J Med. 2021 Feb 25;384(8):705-716. (PMID: 33626253)
Leuk Res. 2014 Jan;38(1):23-8. (PMID: 24129344)
J Clin Invest. 2016 Dec 1;126(12):4640-4653. (PMID: 27841764)
Nat Chem Biol. 2020 Nov;16(11):1208-1217. (PMID: 32958952)
Nature. 2008 Jul 10;454(7201):226-31. (PMID: 18568025)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Leukemia. 2017 Oct;31(10):2104-2113. (PMID: 28186131)
Leukemia. 2012 Nov;26(11):2326-35. (PMID: 22552008)
Cell Chem Biol. 2019 Mar 21;26(3):340-351.e3. (PMID: 30612952)
Blood Adv. 2020 Apr 28;4(8):1628-1639. (PMID: 32311014)
Leuk Lymphoma. 2019 Jan;60(1):180-188. (PMID: 29718735)
Leukemia. 2016 Mar;30(3):761-4. (PMID: 26174630)
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16420-16429. (PMID: 31371506)
Science. 2014 Jan 17;343(6168):301-5. (PMID: 24292625)
Leukemia. 2010 Aug;24(8):1506-12. (PMID: 20555361)
Blood Cancer J. 2019 Feb 11;9(2):19. (PMID: 30741931)
Blood. 2013 Jan 24;121(4):624-7. (PMID: 23233657)
Nat Rev Dis Primers. 2017 Jul 20;3:17046. (PMID: 28726797)
Oncotarget. 2010 May;1(1):22-33. (PMID: 20930946)
Cancer Cell. 2019 Nov 11;36(5):483-497.e15. (PMID: 31679823)
Mol Cancer Ther. 2017 Nov;16(11):2375-2386. (PMID: 28878026)
Blood Cancer J. 2015 Oct 02;5:e354. (PMID: 26430725)
Clin Cancer Res. 2019 Mar 15;25(6):1923-1935. (PMID: 30610101)
BMC Cancer. 2018 May 10;18(1):551. (PMID: 29747599)
Blood. 2019 Jul 11;134(2):160-170. (PMID: 31043423)
Cancer Cell. 2013 Jan 14;23(1):48-62. (PMID: 23328480)
Leukemia. 2018 Feb;32(2):391-401. (PMID: 28676669)
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16669-74. (PMID: 21949397)
Mol Pharmacol. 2019 Mar;95(3):286-293. (PMID: 30591537)
Blood. 2011 Nov 3;118(18):4771-9. (PMID: 21860026)
Autophagy. 2015;11(7):1161-78. (PMID: 26043024)
Cancer Chemother Pharmacol. 2013 May;71(5):1357-68. (PMID: 23589314)
Leukemia. 2019 Sep;33(9):2266-2275. (PMID: 30858549)
Sci Transl Med. 2019 Mar 27;11(485):. (PMID: 30918115)
J Am Soc Nephrol. 2006 Jul;17(7):1807-19. (PMID: 16738015)
Nat Med. 2016 Jul;22(7):735-43. (PMID: 27294876)
Blood. 2013 Jan 10;121(2):318-28. (PMID: 23169779)
N Engl J Med. 2015 Sep 24;373(13):1207-19. (PMID: 26308596)
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9946-51. (PMID: 12902539)
Blood. 2006 Jun 15;107(12):4907-16. (PMID: 16507771)
Leukemia. 2019 Jan;33(1):171-180. (PMID: 30026574)
Blood. 2014 Jul 24;124(4):536-45. (PMID: 24914135)
Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):382-387. (PMID: 28028240)
Nat Immunol. 2013 Mar;14(3):298-305. (PMID: 23354484)
Nat Commun. 2017 Aug 16;8(1):268. (PMID: 28814763)
Nat Commun. 2014;5:2997. (PMID: 24429703)
Blood. 2012 Aug 2;120(5):1067-76. (PMID: 22498740)
Blood. 2012 Sep 20;120(12):2450-3. (PMID: 22806891)
Drugs. 2018 Jan;78(1):19-37. (PMID: 29188449)
BMC Cancer. 2018 Nov 21;18(1):1152. (PMID: 30463534)
Blood. 2016 Jun 2;127(22):2693-700. (PMID: 27009059)
Leukemia. 2019 Feb;33(2):447-456. (PMID: 30026573)
Cancer Metab. 2017 Aug 29;5:7. (PMID: 28855983)
Haematologica. 2020 May;105(5):e237-e241. (PMID: 31558666)
Int J Hematol. 2016 Sep;104(3):293-9. (PMID: 27460676)
Lancet Oncol. 2020 Dec;21(12):1630-1642. (PMID: 33129376)
Clin Cancer Res. 2021 Feb 1;27(3):819-830. (PMID: 33109736)
Clin Cancer Res. 2019 Jan 1;25(1):90-98. (PMID: 30201761)
N Engl J Med. 2019 May 2;380(18):1726-1737. (PMID: 31042825)
N Engl J Med. 2019 Aug 22;381(8):727-738. (PMID: 31433920)
J Clin Invest. 2018 Jul 2;128(7):2877-2893. (PMID: 29863498)
N Engl J Med. 2015 Aug 13;373(7):621-31. (PMID: 26035255)
Oncotarget. 2014 Dec 15;5(23):11986-97. (PMID: 25230277)
Mol Cancer Ther. 2013 Jun;12(6):1140-50. (PMID: 23536725)
Exp Ther Med. 2019 Aug;18(2):1057-1068. (PMID: 31363365)
Cancer Cell. 2017 Mar 13;31(3):396-410. (PMID: 28262554)
Oncotarget. 2016 Oct 25;7(43):70845-70856. (PMID: 27683126)
Ann Hematol. 2019 Jan;98(1):19-28. (PMID: 30073393)
Oncotarget. 2014 Dec 15;5(23):12358-70. (PMID: 25481044)
Leukemia. 2016 Nov;30(11):2198-2207. (PMID: 27118406)
Blood. 2015 Jun 25;125(26):4042-51. (PMID: 25869284)
J Med Chem. 2018 Jan 25;61(2):535-542. (PMID: 28425720)
Science. 2014 Jan 17;343(6168):305-9. (PMID: 24292623)
Leukemia. 2017 Jun;31(6):1363-1367. (PMID: 28017969)
J Clin Oncol. 2021 Mar 1;39(7):757-767. (PMID: 33296242)
Blood. 2008 Sep 15;112(6):2489-99. (PMID: 18565852)
J Immunol. 2016 Aug 1;197(3):807-13. (PMID: 27316683)
Leukemia. 2020 Jan;34(1):245-256. (PMID: 31439945)
Oncotarget. 2015 Sep 29;6(29):26922-34. (PMID: 26323097)
Haematologica. 2018 Dec;103(12):2088-2096. (PMID: 30237262)
N Engl J Med. 2016 Oct 6;375(14):1319-1331. (PMID: 27705267)
Clin Cancer Res. 2017 Jul 1;23(13):3307-3315. (PMID: 28053023)
Blood. 2009 Jul 23;114(4):772-8. (PMID: 19471019)
Haematologica. 2018 Aug;103(8):e368-e371. (PMID: 29545338)
Blood. 2016 Aug 18;128(7):959-70. (PMID: 27307294)
Leukemia. 2017 Feb;31(2):382-392. (PMID: 27479184)
Blood. 2020 Apr 9;135(15):1232-1243. (PMID: 32040549)
Leukemia. 2020 Apr;34(4):1197-1201. (PMID: 31719682)
Science. 2018 Nov 2;362(6414):. (PMID: 30385546)
Blood Cancer J. 2019 Mar 20;9(4):37. (PMID: 30894515)
Lancet. 2020 Nov 14;396(10262):1563-1573. (PMID: 33189178)
Biomed Pharmacother. 2002 May;56(3):115-28. (PMID: 12046682)
معلومات مُعتمدة: K08 CA222704 United States CA NCI NIH HHS; K08CA222704 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: clinical trials; drug resistance; immunomodulatory drugs; immunotherapy; monoclonal antibodies; multiple myeloma; proteasome inhibitors; resistance mechanisms; treatment
تواريخ الأحداث: Date Created: 20210430 Latest Revision: 20210609
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8038312
DOI: 10.3390/cancers13071686
PMID: 33918370
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13071686